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Abstract—A computational study at the density functional theory level was performed on bioactive and model sulfonamides with the aim of
determining the factors affecting the acidity of the sulfonamido group. The effects of introducing different substituents at either the para-aryl
or the N1-sulfonamide positions were independently analyzed. A linear correlation was found between sulfonamide acidity and the Hammett
constants or charge of the SO2 group of substituents at the para-aryl position. Most N
1-substituents were taken from bacteriostatic
sulfonamide structures and presented a more complex behavior, possibly due to a conjugation of steric and electronic factors. In the latter
situation, sulfonamide acidity and the charge of the SO2 group were not linearly correlated. Interestingly, the acidity of the sulfonamido
group was found to be correlated with the reactivity of sulfa drugs towards acylating agents. The implications for the design of suitable
sulfonamide prodrugs are discussed.
q 2005 Elsevier Ltd. All rights reserved.1. Introduction
The characterization of sulfonamides as chemotherapics is
more than half a century old.1 Since then, the sulfonamido
group—SO2NH—has been found as a key structural motif
shared by a large number of bioactive compounds, spanning
a wide variety of biological effects, such as antimicrobial
activity, specific enzyme inhibition, hormone regulation,
among others.2 The most popular sulfonamides are
p-aminobenzensulfonamides, or sulfanilamides (1), which
are bacteriostatic due to their resemblance to p-aminoben-
zoic acid (PABA, 2), used by bacteria in the biosynthesis of
the folic acid required for their growth.3
Most bacteriostatic sulfonamides are characterized by a
p-aminoaryl moiety and structural diversity has been
obtained basically by variation of the R-group linked to0040–4020/$ - see front matter q 2005 Elsevier Ltd. All rights reserved.
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group is a heterocyclic structure that renders the compound
several times more active than the original sulfanilamide
(RZ–H). In the early days of sulfonamide therapy,
experimental studies by Bell et al.4 Kumler et al.5,6 and,
20 years later, Seydel,7 have been devoted to the analysis of
stereoelectronic factors that could be related to bacterio-
static activity, paying special attention to the role of the
acidity of the sulfonamido group.4,7 These studies suggested
that bacteriostatic activity is favored by decreased sulfona-
mide acidity (larger DG8 values), which was confirmed in a
very recent theoretical work published by Soriano-Correa
and co-workers.8 Also, distinct therapeutical effects are
often associated to different acidity ranges, as illustrated by
the higher acidity of antiglaucoma sulfas when compared to
their cancerostatic counter parts.9 Thus, it seems that the
acidity of the sulfonamido group, and factors affecting it, are
key features ruling the physico-chemical properties that
modulate the sulfonamide bioactivity.
Due to the well-known problems of sulfonamide therapy,
especially those related to growing bacterial resistance,
adverse effects and low bioavailability,10–12 we have been
working on the synthesis of N1-acyl and N4-acylsulfanila-
mides as potential prodrugs of antimalarial sulfonamides.
These antimalarials were acylated with amino acids and
dipeptides, which are interesting carriers for drug delivery
in vivo. Dipeptide carriers have several advantages, since
they are non-toxic, non-immunogenic and can trigger theTetrahedron 61 (2005) 2705–2712
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tion in the gastro-intestinal tract.13–16 Also, dipeptide-based
prodrugs can be activated by a strictly chemical process, an
intramolecular cyclization to a 2,5-diketopiperazine, and,
thus, not subject to biological variability.13,17–19 The
development of efficient sulfonamide prodrugs is a priority
in medicinal chemistry, since sulfonamides such as
sumatriptan (a 5-HT1 agonist for migraine treatment),
acetazolamide (antiglaucoma carbonic anhydrase inhibitor)
or nimesulide (anti-inflamatory COX-2 inhibitor) still suffer
from several problems related to low bioavailability or
serious adverse effects.10,11,20 Further, N-acylated and
amino acid based sulfonamides are emerging as potential
antiviral and antitumoral drugs21,22 and, thus, a detailed
description of N-acylsulfonamides is mandatory.
In a previous experimental work, we found that sulfanil-
amide acylation was regiosselective (Scheme 1) and that
the degree of regiosselectivity and reactivity depended of
the drug employed.13 This prompted us to perform a brief
computational analysis of the geometrical and thermo-
dynamic factors ruling the acylation reactions between
amino acid glycine and four sulfanilamides, in order to
explain our experimental findings.13 We now wish to
present an extensive computational study of the gas-phase
acidity of both bioactive and model sulfonamides, in order
to evaluate the relevance of this property on their reactivity
towards acylating agents. Implications of the present study
for prodrug design will be discussed.2. Computationals details
In the present work, the density functional theory based
B3LYP three-parameter hybrid method proposed by
Becke23 was used for all the calculations. These compu-
tations were performed by means of the GAMESS-US24 and
Gaussian 9825 suites of programs. The B3LYP method
comprises an exchange-correlation functional that mixes the
non-local Fock exchange with the gradient-corrected form
of Becke23 and adds the correlation functional proposed by
Lee et al.26 The use of the B3LYP method is known to be an
excellent computational choice both to obtain geometric andScheme 1.thermodynamic data.27–29 In fact, the three a, b and c
parameters in this hybrid approach were determined by
fitting to experimental thermochemical data which include
atomization energies, ionization energies, proton affinities
and atomic energies of a large set of molecules.23 Very
recently, several different thermochemical properties have
been computed at the B3LYP level of theory and the results
obtained compare excellently with available experimental
data.29,30–36
In the DFT calculations, the geometry optimization runs
were performed without symmetry constraints for all
compounds considered and the atomic electronic density
of all atoms was described by the standard 6-31CG(d) basis
set. The calculation of frequencies was performed to ensure
that a minimum is located and also to correct total energies
by including the Zero-Point Energies, ZPE, as well as
translational (HT), rotational (HR) and vibrational (HV)
contributions to the enthalpy at TZ298.15 K. Then, a
single-point energy calculation (E0) was performed at the
B3LYP/6-311CG(2d,2p) level of theory on the 6-31CG(d)
optimized geometries. The thermally corrected enthalpy of
species A is calculated as:
HðA; 298:15 KÞZE0ðBLÞCZPEðBSÞCHTðBSÞ
CHRðBSÞCHVðBSÞCRT (1)
where BL and BS stand for basis large (6-311CG(2d,2p))
and basis small (6-31CG(d)), respectively, and RT results
from the PV term.
From previous experience, the use of this combined
strategy, B3LYP/6-311CG(2d,2p)//B3LYP/6-31CG(d)
approach, yields identical results to that obtained from
full-optimization and frequencies calculations performed at
the B3LYP/6-311CG(2d,2p) level,31–33 i.e. where all terms
in equation (1) are computed using the large basis. In these
works, the combined approach was tested for several
different thermodynamic properties, such as enthalpies of
formation, bond dissociation enthalpies, gas-phase acidities
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gas-phase acidity was calculated as:
DG8ZDH8KTDS8 (2)
with the enthalpic difference (DH8) associated to the
reaction SULFA-H/SULFAK CHC given as:
DH8ZH8ðSULFAKÞCH8ðHCÞKH8ðSULFAKHÞ (3)
This equation may be simplified to
DH8ZH8ðSULFAKÞKH8ðSULFAKHÞC5=2RT (4)
since the enthalpy of the proton is reduced to the sum of the
contributions from translational motion (HTZ3/2RT) and
from the pV term. The gas-phase acidity computed with the
combined strategy (BL and BS basis sets) for p-aminoben-
zenesulfonamide was tested against the gas-phase acidity
obtained with the B3LYP/6-311CG(2d,2p) approach; the
two results differ by only 0.1 kJ/mol.3. Results and discussion
3.1. Effects of R1 and R2 on sulfonamide acidity
In a previous experimental and theoretical work we found
that the acylation of four different para-aminobenzenesul-
fonamides with glycine was regiosselective and governed
by a combination of geometrical, thermodynamic and
electronic factors.13 These findings drove us to the present
study, where the influence of the sulfonamido group acidity
on chemical reactivity and other sulfonamide properties is
discussed. We analyzed separately the effects on sulfona-
mido acidity of: (i) the R1 group (para-aryl substituent) and,
(ii) the R2 group attached to N1 (3). We chose groups that
were either present in bioactive sulfonamides or useful to
establish structure–activity relationships (SAR).
In Table 1, a compilation of the most interesting geometric
parameters is reported for several different para-R1-
benzenesulfonamides, with R1ZH, F, Cl, OH, CN, NH2,
NO2, CH3 and OCH3. The R
1 substituents were chosen inTable 1. Selected geometrical parameters, enthalpies of inversion and gas-phase a
the B3LYP//6-311CG(2d,2p)//B3LYP/6-31CG(d) level of theory
R1 (R2ZH) Geometrical parameters (A˚)
d(S]O) d(Ar–S) d(S–N)
–H 1.468/1.468 (1.488/1.500) 1.797 (1.842) 1.700 (1
–F 1.468/1.468 (1.488/1.500) 1.794 (1.843) 1.700 (1
–Cl 1.468/1.468 (1.487/1.499) 1.796 (1.843) 1.699 (1
–OH 1.469/1.469 (1.489/1.502) 1.788 (1.843) 1.702 (1
–CN 1.467/1.467 (1.486/1.497) 1.803 (1.840) 1.695 (1
–NH2 1.470/1.470 (1.490/1.502) 1.783 (1.841) 1.705 (1
–NO2 1.466/1.466 (1.484/1.496) 1.804 (1.834) 1.693 (1
–CH3 1.469/1.469 (1.489/1.501) 1.793 (1.841) 1.702 (1
–OCH3 1.470/1.469 (1.489/1.502) 1.787 (1.841) 1.703 (1
Geometrical parameters given in parenthesis refer to the corresponding anionic fsuch a way that a wide range of Hammett constants could be
spanned, allowing us to analyse the effect of varying
substituents from those having large electron withdrawing
effects to those with large electron donation capacity. A
close inspection of parameters given in Table 1 shows that
the length of the N–H bond that may suffer heterolytic
cleavage upon acylation with amino acids is unaffected by
the electronic effects imposed by the different R1 groups
tested. This is also the case for the S]O bond lengths,
which vary between 1.466 and 1.470 A˚. This is in clear
contrast with the significantly larger variations found for the
ring-sulfur bond lengths. Such behavior suggests that only
the sulfur atom is largely affected by the presence of
different groups attached to the aromatic ring at the para
position, leaving the oxygen atoms lessly affected. When
compared with R1ZH, electron donating groups such as
NH2 lead to an increase in the S]O and S–N bond lengths,
and to a decrease in the Ar–S distance. The opposite is found
for R1ZNO2, where S]O and S–N bonds are shortened
and the Ar–S bond length is enlarged. In all compounds
studied, the non-planar O]S]O group is cis-oriented with
the H–N1–H 0 bonds. The small influence of the R1
substituent on the sulfonamido group is also noticed from
the slight variation in the H–N1–S–H 0 dihedral angle, which
varies between 121.7 and 123.88 for R1ZNH2 and R
1Z
NO2, respectively.
Table 1 also displays the enthalpies of inversion for the
different compounds considered, calculated as the differ-
ence between the enthalpy at TZ298.15 K for the fully-
optimized H–N1–H 0 trans-oriented geometry and that for
the H–N1–H 0 cis-oriented species. The values lie in the 2.8–
4.9 kJ/mol range, respectively, for NH2 and NO2 groups,
and are correlated with the calculated S–N bond lengths.
Indeed, the shorter S–N bond in the nitro-substituted
compound is responsible for a less effective accommodation
of the nitrogen atom lone-pair, when compared to its amino-
substituted counterpart, thus explaining the different
enthalpies of inversion found.
Gas-phase acidities calculated as DG8 at the B3LYP/6-
311CG(2d,2p)//B3LYP/6-31CG(d) level of theory, are
also reported in Table 1. This thermodynamic property is a
direct measure of the promptness of the sulfonamido group
to lose one proton during the acylation reaction. The DG8
calculated for the nine different R1-substituted sulfonamides
show that, despite the large intramolecular distance between
the para-substituent and the sulfonamido group, thiscidities of benzenesulfonamides substituted at the R1 position computed at
DH8 (kJ/mol) DG8 (kJ/mol)
d(N–H) Inversion Acidity
.582) 1.018 (1.024) 3.6 1402.8
.580) 1.019 (1.024) 4.4 1391.4
.580) 1.019 (1.024) 4.2 1385.2
.580) 1.019 (1.024) 3.6 1407.2
.579) 1.019 (1.024) 4.7 1361.1
.581) 1.019 (1.024) 2.8 1421.9
.581) 1.018 (1.024) 4.9 1352.2
.582) 1.019 (1.024) 3.6 1404.3
.581) 1.019 (1.024) 3.5 1411.0
orms.
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clearly depicted in Fig. 1(a), where the calculated DG8 are
plotted against the Hammett s constants for the different R1
employed.37 A clear correlation is observed (r2Z0.94),
showing that the calculated DG8 strongly depend on the
electronic effects of the nine R1 substituents studied. This
dependence is reflected by free energy differences as high as
70 kJ/mol, found between the para-amino- and the para-
nitrobenzenesulfonamides. This is an extremely important
finding, since it shows that substitution at R1 is also
responsible for the different acidities that characterize
sulfonamide-based drugs.Figure 1. Correlation between calculated gas-phase acidities (as DG8) of
R1-3 compounds and (a) Hammett s constants for the R1 substituent; (b) the
charge in the SO2 group.
 
Figure 2. Potential energy surface for the rotation of the phenyl ring around
the ring-S axis calculated at the B3LYP/6-31CG(d) level of theory. The
x-axis values of 0 and 1808 mean that the aromatic ring lies between the
SO2 moiety.Depending on the substituent considered, calculated charges
at the sulfonamido group and derived from a Natural
Population Analysis38 show larger variations in oxygen
and sulfonamido hydrogen atoms than in nitrogen and
sulfur. In an earlier work of Bell et al.4 concerning only
N1-substituted sulfanilamides, 1, an increase of the
compound acidity (which is equivalent to a decrease in
DG8) was found to cause a decrease in the SO2 group
negative charge and in bacteriostatic activity. The variation
of calculated DG8 with the charge of the SO2 group is
depicted in Fig. 1(b). As it can be seen, the correlation
between sulfonamide DG8 and the atomic populations at theSO2 group determined by the para-substituent of the
aromatic ring is now linear (r2Z0.99). This shows that
direct substitution in the aromatic ring has also a great effect
in the charge of the sulfonamido group that is highly
correlated with the electronic effects caused by the
substituent.
In a recent work, Soriano-Correa et al.8 suggested that
sulfonamide activity was accompanied by a small torsion
barrier, i.e. more rigid molecules will be more active. In
order to check the rigidity of sulfonamide, the energetics of
the rotation of the aromatic ring with respect to the
sulfonamido group was calculated for sulfanilamide and is
depicted in Fig. 2. At the B3LYP/6-31CG(d) level of
theory, the calculated energy barrier is of about 8.5 kJ/mol,
slightly lower than for C–C rotation in ethane (w12 kJ/
mol). This suggests almost free rotation around the Ar–S
bond, despite the neighboring oxygen atoms of the
sulfonamido group. The calculated energy of rotation will
be valid for the generality of sulfanilamides since
substitution at both R1 and R2 positions will not sterically
affect the ring-S bond rotation.As mentioned above, despite the large distance between R1
and N1 positions, the R1 substituent seems to have a crucial
role in the acidities of sulfonamide derivatives. An
enhanced effect in the chemical and biological properties
that distinguish different sulfonamide-based drugs should be
expected if N1 substitution takes place due to its proximity
to the leaving proton. Thus, the role of different R2 groups
attached to the N1 atom should be equally inspected. In view
of this, we analyzed the influence of several different R2
substituents on the structure of the sulfonamido group, as
reported in Table 2. The substituents were chosen taking
into account the structures of some sulfonamide-based
drugs, with the difference that the para-amino group is now
absent. In comparison with data from Table 1, larger
changes in the internal geometry of the sulfonamido group
are now observed, as expected from the closer distance
between the substituent group and the sulfur atom. First, if
an oxygen atom is placed in a position adjacent to the
carbon-sulfonamido nitrogen bond (two last entries in Table
2), the S–N bond length is noticeably increased when
Table 2. Selected geometrical parameters and gas-phase acidities of benzenesulfonamides substituted at the R2 position computed at the B3LYP//6-311C
G(2d,2p)//B3LYP/6-31CG(d) level of theory
R2 (R1ZH) Geometrical parameters (A˚) DG8 (kJ/mol)
d(S]O) d(Ar–S) d(S–N) d(N–H) d(N-R2) Acidity
–H 1.468/1.468 (1.488/1.500) 1.797 (1.842) 1.700 (1.582) 1.018 (–) 1.018 (1.024) 1402.8
–NH2 1.468/1.473 (1.484/1.500) 1.795 (1.837) 1.730 (1.615) 1.021 (–) 1.411 (1.451) 1415.9
–NO2 1.463/1.457 (1.478/1.478) 1.784 (1.820) 1.768 (1.676) 1.021 (–) 1.403 (1.350) 1289.6
1.466/1.463 (1.482/1.493) 1.800 (1.830) 1.704 (1.598) 1.017 (–) 1.425 (1.382) 1367.7
1.469/1.471 (1.485/1.498) 1.800 (1.839) 1.685 (1.579) 1.018 (–) 1.477 (1.449) 1385.8
1.467/1.461 (1.481/1.484) 1.794 (1.826) 1.711 (1.624) 1.017 (–) 1.390 (1.347) 1360.8
1.468/1.461 (1.482/1.484) 1.794 (1.827) 1.710 (1.623) 1.016 (–) 1.392 (1.348) 1366.0
1.468/1.461 (1.482/1.484) 1.795 (1.827) 1.707 (1.621) 1.017 (–) 1.394 (1.350) 1370.3
1.463/1.465 (1.479/1.495) 1.799 (1.830) 1.708 (1.596) 1.020 (–) 1.415 (1.372) 1354.9
1.464/1.462 (1.479/1.489) 1.798 (1.825) 1.701 (1.614) 1.017 (–) 1.401 (1.357) 1344.2
1.463/1.463 (1.481/1.494) 1.798 (1.832) 1.706 (1.594) 1.019 (–) 1.400 (1.370) 1350.2
1.464/1.462 (1.480/1.489) 1.797 (1.824) 1.725 (1.601) 1.019 (–) 1.393 (1.355) 1332.6
1.468/1.458 (1.483/1.483) 1.792 (1.827) 1.724 (1.637) 1.016 (–) 1.391 (1.356) 1344.3
Geometrical parameters given in parenthesis refer to the corresponding anionic forms.
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case of a nitrogen atom placed in a position adjacent to the
carbon-sulfonamido nitrogen bond, the S–N bond is less
changed if donor groups are attached to the heterocyclic
ring. This is easily noticed for sulfadiazine, sulfamerazine
and sulfamethazine derivatives, entries 6–8 in Table 2,
where a slight increase in the S–N bond is found when on
going from the sulfamethazine to the sulfadiazine derivative
followed by correspondent slight decrease in the N-R2 bond
length.
For the list of compounds reported in Table 2, the variationof calculated DG8 with the charge of the SO2 group is
depicted in Fig. 3(a). In this case, the correlation between
acidity and charge is not linear, which suggests a rather
different influence caused by the substituent in sulfonamide
acidity. The variation DG8(sulfadiazine)!DG8(sulfamera-
(sulfamerazine)!DG8(sulfamethazine) is associated with a
negligible decrease in the positive charge calculated for the
SO2 group (0.487; 0.486; 0.483 a.u., respectively). These
differences in the SO2 group charge do not seem to be the
only cause for a 6 kJ/mol variation in DG8 between
sulfadiazine and sulfamerazine derivatives, or for 4 kJ/mol
between the sulfamerazine and sulfamethazine derivatives,
Figure 3. Correlation between calculated gas-phase acidities (as DG8) of
R2-3 compounds and (a) the charge in the SO2 group; (b) experimental
pKa’s of the parent sulfa drugs, as reported in Ref. 4.
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DG8 variation. Further, if we consider the sulfamethoxy-
pyridazine and sulfadimethoxine derivatives, both incorpo-
rating methoxyl groups attached to the aromatic ring, a DG8
difference of w10 kJ/mol is now accompanied by a larger
variation in the SO2 group charges, 0.470 and 0.486 a.u. for
sulfamethoxypyridazine and sulfadimethoxine derivatives,
respectively. Also important and contrarily to what was
found for sulfadiazine and methyl substituted sulfadiazine
derivatives, the decrease in DG8 is now associated with a
decrease in the S–N bond length. Finally, the difference
between NPA charges in the SO2 moiety calculated for
sulfamethoxypyridazine and sulfadimethoxine derivatives
is identical to the difference found for sulfadimethoxine and
the NO2-substituted sulfonamide derivatives that corre-
spond to variations in DG8 of 10 and 55 kJ/mol, respec-
tively. Thus, and as observed for R1 substituents, the charge
on the SO2 group cannot be seen as the only factor affecting
sulfonamide acidity. Therefore, a conjugation of geometri-
cal and electronic effects determined by the R1 and R2
substituents, including delocalization through aromatic
rings on either side of the SO2 group, must underlie
sulfonamide reactivity and bioactivity. This should beinterpreted as an addition, and not a correction, to the
suggestions of Bell et al.4
It is noteworthy that the computed acidities herein reported
present some correlation with previously published pKa, as
shown in Fig. 3(b). In fact, if we do not consider the phenyl
derivative, there is a linear correlation, which gives support
to the quality of the computed thermodynamic data reported
in the present work. Following conclusions by Bell et al.4
these data have implications in terms of correlation with
bacteriostatic activity. Indeed, computed acidities for
compounds considered in Fig. 3(b) are somewhat correlated
with the bacteriostatic activities against E. coli reported
by the same authors (data not shown).4 However, the
correlation is not perfect, as one should expect from the fact
that linear correlations have only been found for series of
homologous sulfonamides.4,39,40
The present work is also relevant for sulfonamide
therapeutical properties other than bacteriostatic activity.
Aromatic sulfonamides used to treat glaucoma are known to
exhert their therapeutical action through inhibition of the
human zinc-enzyme carbonic anhydrase II (HCA II). These
sulfonamides bind the zinc dication of HCA II through their
deprotonated sulfonamide nitrogen, thus –SO2NH– acidity
has an important role on sulfonamide ability to inhibit HCA
II. Indeed, recent studies by Remko and co-workers show
that the acidity of common sulfa drugs such as acetazola-
mide, brinzolamide and dorzolamide is correlated with their
Zn2C-binding affinity.41,42
3.2. Implications of sulfonamide reactivity on prodrug
design
As above mentioned, this study was set out to shed some
light on the understanding of the N1 versus N4 acylation
reaction between glycine and four different para-amino-
benzenesulfonamides, previously reported.13 In the present
notation, acylation at position N1 means reaction at the
sulfonamido group while acylation at the N4 nitrogen means
reaction at the 4-anilino group. Experimentally, sulfametha-
zine, sulfamethoxypyridazine, sulfadimethoxine and sulfi-
soxazole were reacted with Na-protected glycine, and both
the position and yield of acylation were seen to vary with
sulfonamide. The yields of N4-acylation with Na-Boc-
GlyOH were 52%, 43% and 41% for the three first
compounds, respectively (Table 3). For sulfisoxazole, high
levels of starting materials were recovered, although
the formation of several products could be detected.
Na-ZGlyOH was also reacted with sulfamethazine and
sulfisoxazole, for comparison purposes. Again, reaction
with sulfamethazine yielded 41% of the N4-derivative,
whereas reaction with sulfisoxazole yielded a complex
mixture from which 8% of the N1-derivative could be
isolated. Thus, it was proposed that sulfisoxazole reacts both
at N1 and N4 with very low yields for both reactions. These
experimental observations seem to be directly correlated
with the acidity of these four sulfas. Data on Table 3 show
that DG8 decreases from sulfamethazine to sulfisoxazole,
which comes associated with a decrease in N4-acylation
yields. Further, lower DG8 values are correlated with lower
energetic barriers for N1-acylation. This shows that, as the
sulfonamide gets more acidic, the easier becomes the
Table 3. Correlation between gas-phase acidity in the sulfonamido group and published experimental yields of N4-acylation and enthalpies for N1-acylation
R2 (R1ZNH2) DG8 (kJ/mol)
a Yield (%) BocGlyOH Yield (%) ZglyOH DH8 (kJ/mol)b sulfaCglycine
1382.5 (C12.2)c 1329.4d (K40.9)e 52 41 76.1
1369.8 (C14.9)c 43 Not tested 68.5
1357.1 (C12.9)c 41 Not tested 50.3
1348.9 (C16.3)c Intractable mixture 8f 34.4
a B3LYP//6-311CG(2d,2p)//B3LYP/6-31CG(d).
b B3LYP//6-311CG(d,p)//B3LYP/6-31CG(d).
c Difference between R1ZNH2 and R
1ZH compounds.
d R1ZNO2.
e Difference between R1ZNO2 and R
1ZH compounds.
f N1-acylation product.
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sulfonamido group (N1).
These findings have obvious implications for the design of
peptide-based sulfonamide prodrugs. The higher acidity of
the –SO2NH– group with respect to the –NH2 group reflects
the relative stabilities of the corresponding conjugate bases.
From the higher stability of SO2N
K with respect to –NHK,
together with the higher steric compression around the N1
atom, one expects the sulfonamide to behave as a better
leaving group from an N1-acylsulfonamide than from an
N4-acylsulfonamide. Indeed, all N4-acylsulfonamides
derived from Na-amino acids and dipeptides prepared in
our laboratory were found to be useless as prodrugs, since
they do not release the parent drug at physiological pH and
temperature, with slow release being observed only under
harsh conditions (pH 12, 60 8C).43 Further, irreversible
acylation at N4 blocks the first site of sulfonamide-enzyme
interaction that underlies the bacteriostatic action of most
sulfa drugs.1 This reinforces the importance of derivatizing
sulfonamides at the –SO2NH– group to produce suitable
prodrugs or novel drugs and, thus, the relevance of acidity
studies on this class of compounds.
The difference between calculated DG8 for sulfonamide
derivatives reported in Table 1 and their parent sulfas listed
in Table 3, i.e. R1ZNH2 and R
1ZH compounds, is also
shown in Table 3. In the case of sulfamethazine, the
calculated DG8 value for the compound with R1ZNO2 is
also given. The differences show that the para-amino still
increases DG8 while the para-nitro group decreases its
value. Further, when R2 is not equal to H the differences in
acidity are slightly decreased but, importantly, its effects on
the final computed acidity follow the same direction asgiven by the values compiled in Table 1. Thus, the Hammett
s constants may be extremely useful for the future design of
sulfa drugs with tailored acidities.4. Conclusions
This theoretical study was set out to analyze the determi-
nants of sulfonamide acidity and the influence of the latter
on sulfonamide reactivity towards acylating agents, such as
amino acids. To achieve our purposes, DFT calculations,
based on the B3LYP method, were carried out to fully
optimize the geometry of all compounds under study and to
extract their enthalpies at TZ298.15 K. These enthalpies
were then used to compute gas-phase acidities of the
sulfonamides. The main conclusions that can be withdrawn
from the present work are:i. There is a linear correlation between sulfonamide
acidity and the Hammett constants of substituents at
the para-aryl position.ii. Sulfonamide acidity was found to be linearly correlated
with the charge of the SO2 group in the case of para-aryl
substitution in agreement with previously reported
works, whereas a conjugation of steric and electronic
factors determined by the N1-substituent seems to
govern sulfonamide acidity.iii. The acidity of the sulfonamido group was found to be
correlated with the reactivity of some sulfa drugs
towards amino acids as acylating agents.iv. The dipeptide carrier approach to design the sulfona-
mide prodrugs will expectedly be more successful with
more acidic sulfas.v. Hammett constants may be useful indicators for the
design of sulfonamides with tailored acidities.
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